111 patents
Utility
Methods of Treating Patients Having Complement Disorders Using ANTI-C5 Antibodies
18 Jan 24
Provided herein are methods of treatment designed to prevent or minimize formation of deleterious multivalent immune complexes in a human patient having a complement mediated disorder (e.g., paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS)), who has been or is being treated with a first anti-C5 antibody and is then treated with a second (different) anti-C5 antibody, as well as methods of safely switching a patient from treatment with a first anti-C5 antibody to a second (different) anti-C5 antibody.
Krista K. Johnson, Paul P. Tamburini, Douglas L. Sheridan
Filed: 22 Oct 21
Utility
Methods of Treating Copper Metabolism-associated Diseases or Disorders
28 Dec 23
This disclosure relates to methods of diagnosing and treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD).
Pan Wei-Jian, Mark Ma, Brian Meltzer, Eugene Scott Swenson, Scott Edward Mosley, Ryan Pelto, Adam Quicquaro, Guillermo del Angel, Hareesh Chamarthi
Filed: 12 Nov 21
Utility
Methods for Treating a Complement Mediated Disorder Caused by Viruses
28 Dec 23
The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by a virus, e.g., corona virus; Dengue virus (DENY); Ross River vims (RRV) and/or influenza virus (flu) by administering an effective amount of a complement modulator, such as, e.g., C5 inhibitor, such as eculizumab or an eculizumab variant or a C5a inhibitor such as olendalizumab (ALXN1007) or a variant thereof, to the subject.
Sharon Barr, Derek Dunn, Xiang Gao, Shamsah D. Kazani, Michele Mercuri, Jonathan Monteleone, Stephan Ortiz, Scott T. Rottinghaus, Martine Zimmermann, Djillali Annane, Veronique Fremeaux-Bacchi, Regis Peffault De Latour
Filed: 16 Apr 21
Utility
Process for Making Recombinant Antidote to Factor Xa Inhibitor
30 Nov 23
Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote.
Genmin Lu, Pamela B. Conley, Uma Sinha
Filed: 22 Mar 23
Utility
Methods for Treating Bone Mineralization Disorders
23 Nov 23
Featured are compositions and methods for treating bone mineralization disorders, such as hypophosphatasia (HPP).
Anna Petryk, Loredana Cuccia
Filed: 2 Sep 21
Utility
Methods of Treating Dermatomyositis
9 Nov 23
The disclosure provides methods of treating a subject having or suspected of having dermatomyositis using a composition including a bi-specific fusion protein.
Paul P. Tamburini
Filed: 5 Oct 21
Utility
Method for Treating Complement Mediated Disorders Caused by Betacoronaviruses
2 Nov 23
The present disclosure provides methods and compositions useful for diagnosing and treating activated alternative pathway of complement in a human subject with a SARS-CoV-2 infection.
Moshe Vardi, Robert A. Brodsky, Xiang Gao, Shamsah D. Kazani, Venu Nagali, Xuan Yuan
Filed: 27 Aug 21
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treating C5-MEDIATED Glomerular Nephritis (GN), Including Lupus Nephritis (LN) And/or Iga Nephropathy (Igan)
2 Nov 23
Provided are dosages and methods for clinical treatment of C5-mediated glomerular nephritis (GN), including lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN), in human patients using an anti C5 antibody, or antigen binding fragment thereof (e.g., such as ravulizumab (ULTOMIRIS®)), optionally together with background therapy for treating LN (e.g., an immuno-suppressant) or background therapy for treating IgAN (e.g., renin-angiotensin system (RAS) inhibiting medication).
Nader Najafian
Filed: 16 Sep 21
Utility
Method of Using Extracellular Vesicles to Detect Complement Activation, and Uses Thereof to Assess And/or Monitor Treatment of a Complement-mediated Disease
2 Nov 23
Disclosed herein are methods of detecting complement activity in a biological sample.
Ellen E. Millman, Tobin J. Cammett
Filed: 13 May 21
Utility
Subcutaneous (SC) Administration of ANTI-C5 Antibodies for Treatment of Complement-associated Conditions
28 Sep 23
Provided are methods for clinical treatment of complement-associated conditions comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule).
Dino C. Miano, Hweirung Amy Wang, Tatyana Mezhebovsky
Filed: 6 May 21
Utility
High Concentration ANTI-C5 Antibody Formulations
17 Aug 23
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-05 antibody (e.g., ravulizumab) and methods for preparing the solutions.
Stephan ORTIZ, Jillian GENTILE, Leena PHILOMINATHAN, Eric ROUTHIER, Bruce MASON
Filed: 21 Dec 22
Utility
Dosage and Administration of ANTI-C5 Antibodies for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) In Pediatric Patients
27 Jul 23
Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients using an anti-C5 antibody, or antigen binding fragment thereof.
Lori Payton, Scott T. Rottinghaus, Rajendra Pradhan, Stephan Ortiz, Masayo Ogawa, Xiang Gao
Filed: 8 Jul 21
Utility
Polypeptides That Bind Complement Component C5 or Serum Albumin and Fusion Proteins Thereof
27 Jul 23
The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin.
Bridget PUFFER, Julian CHANDLER, Nimish GERA, Douglas L. SHERIDAN, Siddharth JINDAL, Paul P. TAMBURINI
Filed: 7 Oct 22
Utility
Methods for Treating Hypophosphatasia In Children and Adolescents
29 Jun 23
The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child or an adolescent having HPP) exhibiting gait impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient and assessing improvement in the gait impairment using a modified Performance-Oriented Mobility Assessment—Gait (mPOMA-G) analysis and score.
Kenji FUJITA, Marc VALLEE, Dawn PHILLIPS
Filed: 21 Nov 22
Utility
Egg White Processing
25 May 23
This disclosure relates to inexpensive and efficient methods of preparing egg white (e.g., obtained from eggs laid by transgenic chickens) for bulk chromatographic isolation of proteins (e.g., recombinant proteins) from the egg white, as well as method of filtering acidified egg white and methods of isolating proteins from the egg white.
Liang CHEN, Markley C. LEAVITT, Michael TITUS
Filed: 11 Nov 22
Utility
ANTI-C5A Antibodies
25 May 23
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Russell P. ROTHER, Douglas L. SHERIDAN, Paul P. TAMBURINI, Yuchun ZHANG
Filed: 27 Jun 22
Utility
Protein a Chromatography Purification of an Antibody
11 May 23
Disclosed are methods for purifying antibodies using a Protein A Chromatography Column and an arginine wash, resulting in decreased host cell protein (HCP) contamination.
Rahul Godawat, Abraham Friedman
Filed: 26 Apr 21
Utility
High Concentration ANTI-C5 Antibody Formulations
6 Apr 23
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions.
Stephan ORTIZ, Jillian GENTILE, Leena PHILOMINATHAN, Eric ROUTHIER, Bruce MASON
Filed: 6 May 22
Utility
Bis-Choline Tetrathiomolybdate for Treating Wilson Disease
9 Mar 23
Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided.
Carl BJARTMAR, Karl-Heinz WEISS, Michael SCHILSKY, Frederick ASKARI, Anna CZLONKOWSKA, Peter FERENCI, Peter HEDERA, Aftab ALA
Filed: 23 Aug 22
Utility
ANTI-C5 Antibody for the Treatment of Neuromyelitis Optica Spectrum Disorder
9 Feb 23
Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.
Kerstin Allen, Marcus Yountz, Stephan Ortiz, Fanny O'Brien
Filed: 8 Dec 20